Boston Scientific Corp. (BSX) won’t begin a study of its hypertension treatment until it can analyze a failed effort by Medtronic Inc. (MDT) and review its approach with U.S. regulators, Chief Executive Officer Michael Mahoney said. While Boston Scientific has Food and Drug Administration backing to start a pivotal trial of its Vessix technology, the company is waiting to see whether the failure of Medtronic’s product in a study last week stemmed from the device or the clinical trial design, or whether the entire approach is invalid. The results of the study may shed light on patient safety and effectiveness of the approach called renal denervation, which lowers blood pressure by damaging the nerves that help fuel it, Mahoney said.
Help employers find you! Check out all the jobs and post your resume.
